Submitted by Anonymous (not verified) on 21 October 2025 - 14:28
Opinion/decision on a Paediatric investigation plan (PIP): Evenity, romosozumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: P/0375/2024
Source: